Calcium, ageing, and neuronal vulnerability in Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Lancet Neurology

• Publication date

  2007-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1474-4422(07)70246-6PMID 17884683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Space, time and dopamine.

  2007cited by this paper
• Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.

  2007cited by this paper
• Inflammation as a causative factor in the aetiology of Parkinson's disease

  2007cited by this paper
• Calcium channel blockers and β-blockers in relation to Parkinson's disease

  2007cited by this paper
• Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?

  2007cited by this paper
• Roles of Subthreshold Calcium Current and Sodium Current in Spontaneous Firing of Mouse Midbrain Dopamine Neurons

  2007cited by this paper
• Characteristics of orthostatic hypotension in Parkinson's disease.

  2007cited by this paper
• Calcium channel blockers and beta-blockers in relation to Parkinson's disease.

  2007cited by this paper
• Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease.

  2007cited by this paper
• ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease

  2007cited by this paper
• Role of voltage-gated L-type Ca2+ channel isoforms for brain function.

  2006cited by this paper
• Microdomains of intracellular Ca2+: molecular determinants and functional consequences.

  2006cited by this paper
• Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons

  2006cited by this paper
• Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson’s disease

  2006cited by this paper
• Expanding insights of mitochondrial dysfunction in Parkinson's disease

  2006cited by this paper
• High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease

  2006cited by this paper
• Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.

  2006cited by this paper
• Neuronal L-Type Calcium Channels Open Quickly and Are Inhibited Slowly

  2005cited by this paper
• G-Protein-Coupled Receptor Modulation of Striatal CaV1.3 L-Type Ca2+ Channels Is Dependent on a Shank-Binding Domain

  2005cited by this paper
• Does levodopa slow or hasten the rate of progression of Parkinson’s disease?

  2005cited by this paper
• Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD

  2005cited by this paper
• Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis.

  2005cited by this paper
• A Mitochondrial Paradigm of Metabolic and Degenerative Diseases, Aging, and Cancer: A Dawn for Evolutionary Medicine

  2005cited by this paper
• Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population.

  2005cited by this paper
• Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians

  2005cited by this paper
• Molecular pathophysiology of Parkinson's disease.

  2005cited by this paper
• Neurodegeneration and neuroprotection in Parkinson disease

  2004cited by this paper
• Stages in the development of Parkinson’s disease-related pathology

  2004cited by this paper
• Biomedicine. Parkinson's--divergent causes, convergent mechanisms.

  2004cited by this paper
• Calcium channel blockers: an update.

  2004cited by this paper
• Parkinson's--Divergent Causes, Convergent Mechanisms

  2004cited by this paper
• Histological changes of the dopaminergic nigrostriatal system in aging

  2004cited by this paper
• Parkinson's Disease Mechanisms and Models

  2003cited by this paper
• Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease.

  2003cited by this paper
• Dopamine controls the firing pattern of dopamine neurons via a network feedback mechanism

  2003cited by this paper
• Neuronal CaV1.3α1 L-Type Channels Activate at Relatively Hyperpolarized Membrane Potentials and Are Incompletely Inhibited by Dihydropyridines

  2001cited by this paper
• α1D (Cav1.3) Subunits Can Form L-type Ca2+ Channels Activating at Negative Voltages*

  2001cited by this paper
• Functional expression and characterization of a voltage-gated CaV1.3 (alpha1D) calcium channel subunit from an insulin-secreting cell line.

  2001cited by this paper
• Age-related cognitive deficits mediated by changes in the striatal dopamine system.

  2000cited by this paper
• Coupled oscillator model of the dopaminergic neuron of the substantia nigra.

  2000cited by this paper
• The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry.

  1999cited by this paper
• Can Calcium Antagonists Provide a Neuroprotective Effect in Parkinson’s Disease?

  1999cited by this paper
• The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

  1999cited by this paper
• Blockade of SK-type Ca2+-activated K+ channels uncovers a Ca2+-dependent slow afterdepolarization in nigral dopamine neurons.

  1999cited by this paper
• Neuronal calcium signaling.

  1998cited by this paper
• GABAergic control of the firing pattern of substantia nigra dopaminergic neurons.

  1998cited by this paper
• L-Type Calcium Channels Mediate a Slow Excitatory Synaptic Transmission in Rat Midbrain Dopaminergic Neurons

  1998cited by this paper
• Calbindin-D28k buffers intracellular calcium and promotes resistance to degeneration in PC12 cells.

  1998cited by this paper
• Responses of rat substantia nigra dopamine‐containing neurones to (−)‐HA‐966 in vitro

  1997cited by this paper
• Apamin‐sensitive Ca2+-activated K+ channels regulate pacemaker activity in nigral dopamine neurons

  1996cited by this paper
• Origin and functional consequences of the complex I defect in Parkinson's disease

  1996cited by this paper
• Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.

  1996cited by this paper
• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.

  1996cited by this paper
• Apamin-sensitive Ca2+-activated K+ channels regulate pacemaker activity in nigral dopamine neurons

  1996cited by this paper
• D2 Receptor Blockade by Flunarizine and Cinnarizine Explains Extrapyramidal Side Effects. A SPECT Study

  1995cited by this paper
• Post-receptor mechanisms underlying striatal long-term depression

  1994cited by this paper
• Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients.

  1993cited by this paper
• Midbrain Dopaminergic Cell Loss in Parkinson's Disease and MPTP‐Induced Parkinsonism: Sparing of Calbindin‐D25k—Containing Cells a

  1992cited by this paper
• Disease‐specific patterns of locus coeruleus cell loss

  1992cited by this paper
• Calbindin‐D28K in the basal ganglia of patients with parkinsonism

  1992cited by this paper
• Pharmacology of calcium channels in cardiac muscle, vascular muscle, and neurons.

  1991cited by this paper
• Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease

  1991cited by this paper
• Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

  1990cited by this paper
• Compensations after lesions of central dopaminergic neurons: some clinical and basic implications.

  1990cited by this paper
• Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

  1988cited by this paper
• Preservation of hypothalamic dopaminergic neurons in Parkinson's disease

  1985cited by this paper
• Membrane properties of rat locus coeruleus neurones.

  1984cited by this paper
• The control of firing pattern in nigral dopamine neurons: single spike firing

  1984cited by this paper
• Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems.

  1979cited by this paper
• Time course of nigrostriatal degeneration in parkinson's disease

  1976cited by this paper
• The Biologic Clock: The Mitochondria?

  1972cited by this paper
• Parkinsonism

  1967cited by this paper
• Dopamine (3-hydroxytyramine) and brain function.

  1966cited by this paper

• A neuropeptide receptor-enriched transcriptional state characterizes resilient dopaminergic neurons in Parkinson's disease.

  2026cites this paper
• Regional heterogeneity of striatal cholinergic interneurons: setting the stage for diverse behavioral repertoires

  2026cites this paper
• The impact of BST1 rs4698412 variant on Parkinson’s disease progression in a longitudinal study

  2025cites this paper
• The Drosophila escape motor circuit shows differential vulnerability to aging linked to functional decay

  2025cites this paper
• Imaging advances to detect non-motor prodromal markers of Parkinson’s disease and explore therapeutic translation opportunities

  2025cites this paper
• Effects of pre-gestational exposure to the stressors and perinatal mirtazapine administration on the excitability of hippocampal glutamate and brainstem monoaminergic neurons, hippocampal neuroplasticity, and anxiety-like behavior in rats

  2025cites this paper
• Recovery of the full in vivo firing range in post-lesion surviving DA SN neurons associated with Kv4.3-mediated pacemaker plasticity

  2025cites this paper
• N-Homocysteinylation of lysine residues in α-Synuclein enhances aggregation propensity and cytotoxicity in SH-SY5Y cells

  2025cites this paper
• Synergistic Effects of Cerebrolysin and Aerobic Exercise on 6-hydroxydopamine-induced Model of Parkinson Disease in Adult Male Rats

  2025cites this paper
• Resilience to Endoplasmic Reticulum Stress Mitigates Membrane Hyperexcitability Underlying Late Disease Onset in a Murine Model of SCA6

  2025cites this paper
• Microsaccade Activity During Visuospatial Working Memory in Early-Stage Parkinson’s Disease

  2025cites this paper
• Endoplasmic Reticulum Stress Inhibition Promotes Mitophagy via Miro1 Reduction to Rescue Mitochondrial Dysfunction and Protect Dopamine Neurons in Parkinson’s Disease

  2025cites this paper
• Inhibition of EHMT1/2 rescues synaptic damage and motor impairment in a PD mouse model

  2024cites this paper
• Smoking, coffee intake, and Parkinson's disease: potential protective mechanisms and components.

  2024cites this paper
• Identifying potential repurposable medications for Parkinson’s disease through Mendelian randomization analysis

  2024cites this paper
• Coupled action potential and calcium dynamics underlie robust spontaneous firing in dopaminergic neurons

  2024influential citation
• Effects of Calcium Ion Dyshomeostasis and Calcium Ion-Induced Excitotoxicity in Parkinson’s Disease

  2024cites this paper
• Scavenger Receptor Class B Type I Modulates Epileptic Seizures and Receptor α2δ-1 Expression

  2024cites this paper
• Mitochondrial Dysfunction as a Potential Mechanism Mediating Cardiac Comorbidities in Parkinson’s Disease

  2024cites this paper
• Dopaminergic neuron metabolism: relevance for understanding Parkinson’s disease

  2024cites this paper
• Calcium channel blockers and Parkinson’s disease: a systematic review and meta-analysis

  2024cites this paper
• Transformation of mulberry polyphenols by Lactobacillus plantarum SC-5: Increasing phenolic acids and enhancement of anti-aging effect.

  2024cites this paper
• Older adults and individuals with Parkinson’s disease control posture along suborthogonal directions that deviate from the traditional anteroposterior and mediolateral directions

  2024cites this paper
• White Matter Microstructure Alteration in Patients with Drug-Induced Parkinsonism: A Diffusion Tensor Imaging Study with Tract-Based Spatial Statistics.

  2024cites this paper
• Insights into Neurodegeneration in Parkinson's Disease from Single‐Cell and Spatial Genomics

  2023cites this paper
• Mitochondrial calcium cycling in neuronal function and neurodegeneration

  2023influential citation
• Targeting calcium homeostasis and impaired inter-organelle crosstalk as a potential therapeutic approach in Parkinson's disease.

  2023cites this paper
• A Proteome-Wide Effect of PHF8 Knockdown on Cortical Neurons Shows Downregulation of Parkinson’s Disease-Associated Protein Alpha-Synuclein and Its Interactors

  2023cites this paper
• The role of dopamine in NLRP3 inflammasome inhibition: implications for neurodegenerative diseases.

  2023cites this paper
• PINK1 and Parkin regulate IP3R-mediated ER calcium release

  2023cites this paper
• Integrative Roles of Dopamine Pathway and Calcium Channels Reveal a Link between Schizophrenia and Opioid Use Disorder

  2023cites this paper
• A Pilot Study of Ex Vivo Human Prefrontal RNA Transcriptomics in Parkinson’s Disease

  2023cites this paper
• Effects of Dihydropyridines on the Motor and Cognitive Outcomes of Patients with Parkinson's Disease

  2023influential citation
• CNS Ageing in Health and Neurodegenerative Disorders

  2023cites this paper
• Pathophysiological Roles of Auxiliary Calcium Channel α2δ Subunits.

  2023cites this paper
• Brain-targeted liposomes loaded with monoclonal antibodies reduce alpha-synuclein aggregation and improve behavioral symptoms in Parkinson’s disease

  2023cites this paper
• AMPK Signaling Pathway as a Potential Therapeutic Target for Parkinson’s Disease

  2023cites this paper
• Therapeutic effects of phlorotannins in the treatment of neurodegenerative disorders

  2023cites this paper
• Neuromelanin: Its role in the pathogenesis of idiopathic Parkinson's disease and potential as a therapeutic target.

  2023cites this paper
• Co-administration of Nanowired DL-3-n-Butylphthalide (DL-NBP) Together with Mesenchymal Stem Cells, Monoclonal Antibodies to Alpha Synuclein and TDP-43 (TAR DNA-Binding Protein 43) Enhance Superior Neuroprotection in Parkinson's Disease Following Concussive Head Injury.

  2023cites this paper
• TRPM2 as a conserved gatekeeper determines the vulnerability of DA neurons by mediating ROS sensing and calcium dyshomeostasis.

  2023cites this paper
• Protocol for rapid obtention and fractionation of anaerobic bacterial conditioned media to study calcium signaling in enteroendocrine cells

  2022cites this paper
• Magnetic Fields and Magnetically Stimulated Gold-Coated Superparamagnetic Iron Oxide Nanoparticles Differentially Modulate L-Type Voltage-Gated Calcium Channel Activity in Midbrain Neurons.

  2022cites this paper
• Cannabidiol Protects Striatal Neurons by Attenuating Endoplasmic Reticulum Stress

  2022cites this paper
• Recent research progress on metabolic syndrome and risk of Parkinson’s disease

  2022cites this paper
• The role of NURR1 in metabolic abnormalities of Parkinson’s disease

  2022cites this paper
• Proline Metabolism in Neurological and Psychiatric Disorders

  2022cites this paper
• Potential of Therapeutic Small Molecules in Apoptosis Regulation in the Treatment of Neurodegenerative Diseases: An Updated Review

  2022cites this paper
• A striatal plasticity that supports the long-term preservation of motor function in Parkinsonian mice

  2022cites this paper
• Neuroprotective Effect of Piracetam and Vincamine in a Rat Model of Haloperidol-induced Parkinson's Disease

  2022cites this paper
• Upregulation of Ca2+-binding proteins contributes to VTA dopamine neuron survival in the early phases of Alzheimer’s disease in Tg2576 mice

  2022cites this paper
• Ca2+ Dyshomeostasis Links Risk Factors to Neurodegeneration in Parkinson’s Disease

  2022cites this paper
• Protective effect of Curcumin against rotenone- induced Substantia nigra pars compacta neuronal dysfunction

  2021cites this paper
• Regulation of neuronal bioenergetics as a therapeutic strategy in neurodegenerative diseases

  2021cites this paper
• Enhanced tyrosine hydroxylase activity induces oxidative stress, causes accumulation of autotoxic catecholamine metabolites, and augments amphetamine effects in vivo

  2021cites this paper
• TRPM4 mediates a subthreshold membrane potential oscillation in respiratory chemoreceptor neurons that drives pacemaker firing and breathing

  2021cites this paper
• Medical treatment of the motor features of Parkinson disease

  2021cites this paper
• Etiology and pathogenesis of Parkinson disease

  2021cites this paper
• The Thermodynamic Consequences of Parkinson's Disease

  2021cites this paper
• Blocking effect of ferritin on the ryanodine receptor-isoform 2.

  2021cites this paper
• Kv 4 . 3 channel downregulation mediates chronic post-lesional 1 pacemaker acceleration in surviving dopamine substantia nigra 2 neurons

  2021cites this paper
• Drug-induced Parkinsonism: A strong predictor of idiopathic Parkinson’s disease

  2021cites this paper
• Calmodulin and Its Binding Proteins in Parkinson’s Disease

  2021cites this paper
• Mitochondrial dysfunction in neurodegenerative diseases: A focus on iPSC-derived neuronal models.

  2021cites this paper
• Synthesis and Biological Assessment of 4,1-Benzothiazepines with Neuroprotective Activity on the Ca2+ Overload for the Treatment of Neurodegenerative Diseases and Stroke

  2021cites this paper
• Protective effect of curcumin against rotenone-induced substantia nigra pars compacta neuronal dysfunction

  2021cites this paper
• Modulating α-Synuclein Liquid-Liquid Phase Separation.

  2021cites this paper
• Does altering proteasomal activity and trafficking reduce the arborization mediated specific vulnerability of SNpc dopaminergic neurons of Parkinson's disease?

  2020cites this paper
• Mitochondrial gene signature in the prefrontal cortex for differential susceptibility to chronic stress

  2020cites this paper
• Neuronal α2δ proteins and brain disorders

  2020cites this paper
• A Role for SERCA Pumps in the Neurobiology of Neuropsychiatric and Neurodegenerative Disorders.

  2020cites this paper
• Trichloroethylene, a ubiquitous environmental contaminant in the risk for Parkinson's disease.

  2020cites this paper
• A novel alpha-lipoic acid-3-n-butylphthalide conjugate enhances protective effects against oxidative stress and 6-OHDA induced neuronal damage.

  2020cites this paper
• The multi‐faceted role of mitochondria in the pathology of Parkinson’s disease

  2020cites this paper
• Endoplasmic reticulum stress, an important factor in the development of Parkinson's disease.

  2020cites this paper
• Buffering of cytosolic calcium plays a neuroprotective role by preserving the autophagy-lysosome pathway during MPP+-induced neuronal death

  2019cites this paper
• Midbrain Dopaminergic Neurons Differentiated from Human-Induced Pluripotent Stem Cells.

  2019cites this paper
• Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease

  2019cites this paper
• Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout

  2019cites this paper
• Genetic Associations between Voltage-Gated Calcium Channels and Psychiatric Disorders

  2019cites this paper
• The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease

  2019cites this paper
• Unifying Hypothesis of Dopamine Neuron Loss in Neurodegenerative Diseases: Focusing on Alzheimer's Disease

  2019cites this paper
• Cav1.2 regulates osteogenesis of bone marrow‐derived mesenchymal stem cells via canonical Wnt pathway in age‐related osteoporosis

  2019cites this paper
• Glutamate Dysregulation in a TauP 301 L Mouse Model of Alzheimer ' s Disease

  2019cites this paper
• Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences

  2019cites this paper
• 4-Imidazo[2,1-b]thiazole-1,4-DHPs and neuroprotection: preliminary study in hits searching.

  2019cites this paper
• The biology of cognitive decline and reduced survival in Parkinson disease : prognostic factors in a population-based cohort

  2019cites this paper
• Altered function of neuronal L-type calcium channels in ageing and neuroinflammation: Implications in age-related synaptic dysfunction and cognitive decline.

  2018cites this paper
• Parkin in Parkinson’s Disease and Cancer: a Double-Edged Sword

  2018cites this paper
• Ventral Tegmental Area in Prodromal Alzheimer’s Disease: Bridging the Gap between Mice and Humans

  2018cites this paper
• Untangling PTSD and TBI: Challenges and Strategies in Clinical Care and Research

  2018cites this paper
• Altered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice

  2018cites this paper
• Reduced Cytosolic Calcium as an Early Decisive Cellular State in Parkinson’s Disease and Synucleinopathies

  2018cites this paper
• Old wines in new bottles: Repurposing opportunities for Parkinson's disease

  2018cites this paper
• Proteome profiling in the hippocampus, medial prefrontal cortex, and striatum of aging rat

  2018cites this paper
• A simple end-point assay for calcium channel activity.

  2018cites this paper
• Selective basal ganglia vulnerability to energy deprivation: Experimental and clinical evidences

  2018cites this paper
• Mitochondrial calcium signalling and neurodegenerative diseases

  2018cites this paper
• Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the &agr;5 nicotinic acetylcholine receptor subunit

  2018cites this paper
• Commentary: Alpha-Synuclein Aggregates Cause Calcium Dysregulation by Activating Calcium Pump SERCA

  2018cites this paper